{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:27:55Z","timestamp":1774448875377,"version":"3.50.1"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41571-026-01125-2","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:05:55Z","timestamp":1770289555000},"page":"233-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the R\u00b2 horizon: new triplet regimens for relapsed and\/or refractory follicular lymphoma"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard, J. P. et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 37, 1188\u20131199 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1125_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0140-6736(25)01778-7","volume":"407","author":"LH Sehn","year":"2026","unstructured":"Sehn, L. H. et al. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet 407, 133\u2013146 (2026).","journal-title":"Lancet"},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","volume":"407","author":"L Falchi","year":"2026","unstructured":"Falchi, L. et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet 407, 161\u2013173 (2026).","journal-title":"Lancet"},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton, K. M. et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 11, e593\u2013e605 (2024).","journal-title":"Lancet Haematol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01125-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:02:36Z","timestamp":1774443756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01125-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":4,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01125-2","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"5 February 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.J.N. has received honoraria for participation in advisory boards from AstraZeneca, BMS, Genentech, Genmab, Johnson & Johnson, Novartis and Regeneron; and served as principal investigator for the CELESTIMO trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}